Pharma deals remain viable despite China-US trade tensions, legal expert says
Biopharma licensing deals and related intellectual property exchanges remain possible even in the context of recent escalating trade tensions between China and the US, Robert Merges, a co-founder of the Berkeley...To view the full article, register now.
Already a subscriber? Click here to view full article